CoChat
Cited by 168

The DOI matches its Crossref record.

Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

Figlin, R. A., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Négrier, S., Huang, X., Kim, S. T., Chen, I., Motzer, R. J. · 2008 · Journal of Clinical Oncology

Abstract

5024 Background: In a randomized, phase III trial, sunitinib demonstrated statistically significant improvement in progression-free survival (PFS) and objective response rate (ORR) compared to IFN-alfa as first-line therapy in mRCC patients (pts) (P<0.001) [Motzer et al. NEJM 2007;356:115], establishing sunitinib as a new reference standard of care. At the time of last analysis, survival data were not mature. Median overall survival (OS) had not been reached in both treatment groups (HR=0.65; P=0.0219). Methods: Pts with mRCC were randomized 1:1 to receive sunitinib 50 mg orally once daily in 6-wk cycles (4 wks on treatment, 2 wks off) or IFN-alfa (9 MU subcutaneously thrice weekly). The primary endpoint was PFS. Secondary endpoints included ORR, safety and OS. For survival analysis, 390 events are required for a 2-sided, unstratified log-rank test with an overall 2-sided significance level of 0.05 and power of 0.85. Patients were followed for survival and post-study cancer treatment information was collected. The influence of baseline clinical features and previously identified prognostic factors on treatment effect will be analyzed with the use of a Cox proportional hazards model. Results: 750 pts were randomized to study treatment, 375 pts in each arm. Median duration of treatment was 11 mos (range: <1–39) for sunitinib vs 4 mos (range: <1–37) for IFN-alfa. 72 pts on sunitinib (including pts who crossed over from IFN-alfa) and 7 pts on IFN-alfa continue on the study. The updated ORR is 47% (95% CI: 42, 52) for sunitinib vs 12% (95% CI: 9, 16) for IFN-alfa (P<0.000001), including 11 complete responses for sunitinib and 4 for IFN-alfa. Median PFS remains the same as reported previously (11 mos vs 5 mos [P<0.000001]). The most common grade 3/4 treatment-related AEs for the sunitinib group are hypertension (12%), fatigue (11%), diarrhea and hand-foot syndrome (both 8%), and, for IFN-alfa, fatigue (13%) and anorexia (2%). No new unexpected grade 3/4 treatment-related AEs have been observed. Events are sufficient for final OS analysis. Conclusions: Sunitinib remains a reference standard for the first-line treatment of mRCC, with significantly superior efficacy over IFN-alfa. Final survival analysis will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Bayer, Genentech, Novartis, Pfizer, Wyeth Pfizer Bayer, Genentech, Novartis, Pfizer, Wyeth Bayer, Genentech, Pfizer, Wyeth

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.26.15_suppl.5024

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
Figlin, R. A., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Négrier, S., Huang, X., Kim, S. T., Chen, I., & Motzer, R. J.
Venue
Journal of Clinical Oncology
Published
2008-05-20
Volume
26
Issue
15_suppl
Pages
5024-5024
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2210929914
Cited by
168
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.5024
The paper
Figlin, R. A., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Négrier, S., Huang, X., Kim, S. T., Chen, I., & Motzer, R. J. (2008). Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.5024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.